Larvae of the fruit fly Drosophila melanogaster are a powerful study case for understanding the neural circuits underlying behavior. Indeed, the numerical simplicity of the larval brain has permitted the reconstruction of its synaptic connectome, and genetic tools for manipulating single, identified neurons allow neural circuit function to be investigated with relative ease and precision.… Continue reading Rewarding Capacity of Optogenetically Activating a Giant GABAergic Central-Brain Interneuron in Larval Drosophila
Tag: Biochemical Pharmacology
Study offers new method for predicting drug-protein binding affinity
Frontiers of Computer Science (2022). DOI: 10.1007/s11704-022-2163-9″> Interaction fragments of the protein kinase C beta and BDBM2591. Credit: Frontiers of Computer Science (2022). DOI: 10.1007/s11704-022-2163-9 Accurately predicting the drug-protein interaction (DPI) is crucial in virtual drug screening. However, current methodologies tend to allocate equal weighting to amino acids and atoms in encoding protein and drug… Continue reading Study offers new method for predicting drug-protein binding affinity
442-Q CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation
AI SummaryDownregulation of ICAM-1 expression on breast cancer cells allows them to escape antibody-targeted cytotoxicity of NK cells, but this resistance can be reversed by certain treatments. CAR-NK cells are able to overcome ICAM-1-based resistance and NKG2A-mediated inhibition. This has implications for the development of more effective NK cell-based cancer immunotherapies.Background Antitumor activity of natural… Continue reading 442-Q CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation
1147-A TNRX-257, a multifunctional LAG3 antagonist and conditional IL2Rϒ/ss partial agonist, is a novel immune stimulant with high dose tolerability in non-human primates
AI SummaryTNRX-257, a novel LAG3 antagonist, has shown promising pharmacokinetics and bioactivity in pre-clinical studies, indicating its potential for use in treating multiple cancer types.Background Interleukin-2 (IL-2) is a driver of T and NK cell proliferation and activation, and has produced remarkable clinical efficacy in a few cancer patients. However, its clinical use is limited… Continue reading 1147-A TNRX-257, a multifunctional LAG3 antagonist and conditional IL2Rϒ/ss partial agonist, is a novel immune stimulant with high dose tolerability in non-human primates
1527 ENB-003, an ETBR antagonist, in combination with pembrolizumab, shows promise in microsatellite stable platinum refractory/resistant ovarian cancer: data from the ENBOLDEN-101 phase 1B study
Background Endothelin B receptor (ETBR) expression in ovarian cancer is associated with a poor prognosis and tumors that lack tumor infiltrating lymphocytes.1 ETBR expression prevents T-cell trafficking into tumors and ETBR blockade with an ETBR inhibitor (ETBRi) stimulates T-cell infiltration of tumors and enhances efficacy of a cancer vaccine in ovarian cancer models. Similarly, the… Continue reading 1527 ENB-003, an ETBR antagonist, in combination with pembrolizumab, shows promise in microsatellite stable platinum refractory/resistant ovarian cancer: data from the ENBOLDEN-101 phase 1B study
1528 A phase I study of a novel BCMAxCD3 bispecific antibody EMB06 in relapsed or refractory multiple myeloma
Background Despite recent advances in T-cell engager based multiple myeloma therapies, high rate of cytokine release syndrome (CRS) and severe neurotoxicity remains a challenge in clinic. EMB-06 is a novel 2+2 BCMAxCD3 T-Cell engaging bispecific antibody developed based on the EpimAb’s proprietary Fabs-In-Tandem-Immunoglobulin (FIT-Ig®) platform. Differentiated from existing T-cell engagers, EMB-06 comprises tetravalent binding domains… Continue reading 1528 A phase I study of a novel BCMAxCD3 bispecific antibody EMB06 in relapsed or refractory multiple myeloma
1532 A phase 1/2 study of safety, tolerability, and pharmacokinetics of SNS-101, a pH-sensitive anti-VISTA mAb, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors
Background VISTA (V-domain Ig suppressor of T-cell activation) is a significant emerging immuno-oncology target. Despite the therapeutic potential of VISTA inhibition demonstrated in preclinical studies,1 clinical development of anti-VISTA antibodies has been challenging due to dose-limiting on-target cytokine release at sub-therapeutic doses and target mediated drug disposition (TMDD).2 SNS-101 is a fully human IgG1 monoclonal… Continue reading 1532 A phase 1/2 study of safety, tolerability, and pharmacokinetics of SNS-101, a pH-sensitive anti-VISTA mAb, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors
1201-B Characterization of a novel bifunctional anti-PD-L1 antibody-drug conjugate for the treatment of solid tumors
Background Immune checkpoint blockade with PD-(L)1 antibody has become a new standard of treatment for many cancers for its remarkable clinical responses. But only a minority of cancer patients responded to PD-1/PD-L1 blockade therapy due to varieties of resistance mechanisms. Unmet needs persist for patients with relapsed/refractory tumors after PD-1/PD-L1 blockade therapies. Upregulated PD-L1 expression… Continue reading 1201-B Characterization of a novel bifunctional anti-PD-L1 antibody-drug conjugate for the treatment of solid tumors
1538 Cytokine checkpoint discovery in human NK cells
Background Natural Killer (NK) cells can detect and eliminate virally-infected and malignant cells. As such, major efforts are underway to identify pathways that regulate these protective immune functions and exploit these for novel anti-cancer therapies. NK cells are dependent on IL-15 for their differentiation, survival and function within solid tumors, and negative regulators of this… Continue reading 1538 Cytokine checkpoint discovery in human NK cells
629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor
AI SummaryFLX475, a selective CCR4 antagonist, shows promising clinical activity in combination with pembrolizumab in patients with non-small cell lung cancer. The combination therapy is well tolerated and demonstrates encouraging results compared to pembrolizumab monotherapy, supporting its continued development for NSCLC. Summary unavailable.Background FLX475 (tivumecirnon) is a selective CCR4 antagonist designed to block the recruitment… Continue reading 629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor